Please use this identifier to cite or link to this item:
http://hdl.handle.net/11434/2377| Title: | A rare and risky surprise of immunotherapy: Pembrolizumab induced grade 4 neutropenia in renal cell carcinoma |
| Epworth Authors: | Fernando, Savisha Saqib, Ayesha |
| Keywords: | Immune Checkpoint Inhibitors ICI Bladder Cancer Kidney Cancer Sepsis Grade 4 Neutropenia Renal Cell Carcinoma Pembrolizumab Department of Medical Oncology, Epworth HealthCare, Richmond, Victoria, Australia |
| Issue Date: | Aug-2025 |
| Conference Name: | Epworth HealthCare Research Week 2025 |
| Conference Location: | Epworth Research Institute, Victoria, Australia |
| Abstract: | Immune checkpoint inhibitors (ICI) are being increasingly utilized in the treatment of metastatic bladder and kidney cancer, with recent introduction into the perioperative setting too Hematological ICI related adverse events are rare but have a significant mortality rate In this report we describe a case of pembrolizumab induced grade 4 neutropenia in renal cell carcinoma |
| URI: | http://hdl.handle.net/11434/2377 |
| Type: | Conference Poster |
| Type of Clinical Study or Trial: | Case Reports |
| Appears in Collections: | Research Week |
Files in This Item:
| File | Description | Size | Format | |
|---|---|---|---|---|
| ANZUPposterSavishaFernando.pdf | 1.14 MB | Adobe PDF |  View/Open |
Items in Epworth are protected by copyright, with all rights reserved, unless otherwise indicated.